uniQure (NASDAQ:QURE) Receives Average Recommendation of “Moderate Buy” from Analysts

uniQure (NASDAQ:QURE) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $38.89.

QURE has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Mizuho boosted their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. Finally, Guggenheim restated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th.

Insider Buying and Selling

In other news, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares in the company, valued at approximately $2,240,441.70. This represents a 4.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares in the company, valued at $6,574,599.40. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last 90 days. 4.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure in the 4th quarter valued at $38,410,000. Franklin Resources Inc. purchased a new position in shares of uniQure during the third quarter worth about $7,360,000. RTW Investments LP increased its position in uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after acquiring an additional 893,625 shares during the period. Point72 Asset Management L.P. raised its stake in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after acquiring an additional 794,459 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of uniQure in the fourth quarter valued at approximately $13,245,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Trading Up 7.8 %

QURE stock opened at $14.77 on Tuesday. The firm has a market cap of $798.72 million, a P/E ratio of -2.98 and a beta of 0.36. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company’s 50-day simple moving average is $13.80 and its 200-day simple moving average is $10.60.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.